Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

about

Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.The Effect of Pet Therapy and Artist Interactions on Quality of Life in Brain Tumor Patients: A Cross-Section of Art and Medicine in Dialog.

P2860

Q38244843-095F9A7B-6BF0-41BA-95A3-8578624ED1C0 Q52928828-9DA1F363-F928-4E36-BE56-7935AF985E89

P2860

Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Item

http://www.wikidata.org/entity/Q48341221

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Measuring clinical benefit: us ...... y brain tumor clinical trials.

@en

Measuring clinical benefit: use of patient-reported outcomes

@nl

type

Item

label

Measuring clinical benefit: us ...... y brain tumor clinical trials.

@en

Measuring clinical benefit: use of patient-reported outcomes

@nl

prefLabel

Measuring clinical benefit: us ...... y brain tumor clinical trials.

@en

Measuring clinical benefit: use of patient-reported outcomes

@nl

P1476

Measuring clinical benefit: us ...... ry brain tumor clinical trials

@en

P2093

Terri S Armstrong

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group s

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.

Pseudoprogression: relevance with respect to treatment of high-grade gliomas.

ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials

Cancer-related symptoms.

P2888

s11912-012-0276-2

P304

27-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-012-0276-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Terri S Armstrong

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23054936

http://www.w3.org/2001/XMLSchema#string

Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

about

P2860

P2860

Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698